{
    "name": "buprenorphine transdermal",
    "comment": "Rx",
    "other_names": [
        "Butrans"
    ],
    "classes": [
        "Opioid Analgesics",
        "Analgesics",
        "Opioid Partial Agonist"
    ],
    "source": "https://reference.medscape.com/drug/butrans-buprenorphine-transdermal-999581",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Opioids cross the placenta and may produce respiratory depression and psychophysiologic effects in neonates; not recommended for use in women immediately prior to and during labor, when use of shorter-acting analgesics or other analgesic techniques are more appropriate",
            "Neonates whose mothers have been taking opioids chronically may also exhibit withdrawal signs, either at birth and/or in the nursery, because they have developed physical dependence; neonatal opioid withdrawal syndrome, unlike opioid withdrawal syndrome in adults, may be life-threatening and should be treated according to protocols developed by neonatology experts",
            "Lactation: Detected in low concentrations in human milk; breastfeeding not advised"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Detected in low concentrations in human milk; breastfeeding not advised"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": [
                {
                    "type": "Addiction, abuse, and misuse ",
                    "description": [
                        "Risk of opioid addiction, abuse, and misuse, which can lead to overdose and death",
                        "Assess each patientâ€™s risk prior to prescribing and monitor all patients regularly for the development of these behaviors or conditions"
                    ]
                },
                {
                    "type": "Life-threatening respiratory depression",
                    "description": [
                        "Serious, life-threatening, or fatal respiratory depression may occur",
                        "Monitor for respiratory depression, especially during initiation or following a dose increase"
                    ]
                },
                {
                    "type": "Accidental exposure ",
                    "description": [
                        "Accidental of even 1 dose, especially by children, can result in a fatal overdose"
                    ]
                },
                {
                    "type": "Neonatal opioid withdrawal syndrome ",
                    "description": [
                        "Prolonged use during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts",
                        "Syndrome presents as irritability, hyperactivity and abnormal sleep pattern, high pitched cry, tremor, vomiting, diarrhea and failure to gain weight",
                        "Onset, duration, and severity of neonatal opioid withdrawal syndrome vary based on the specific opioid used, duration of use, timing and amount of last maternal use, and rate of elimination of the drug by the newborn",
                        "If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available"
                    ]
                },
                {
                    "type": "Opioid analgesic risk evaluation and mitigation strategy (REMS)",
                    "description": [
                        "To ensure that benefits of opioid analgesics outweigh risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a REMS for these products; under requirements of the REMS, drug companies with approved opioid analgesic products must make REMS-compliant education programs available to healthcare providers",
                        "Healthcare providers are strongly encouraged to:",
                        "Complete a REMS-compliant education program,",
                        "Counsel patients and/or their caregivers, with every prescription, on safe use, serious risks, storage, and disposal of these products,",
                        "Emphasize to patients and their caregivers the importance of reading the Medication Guide every time it is provided by their pharmacist",
                        "Consider other tools to improve patient, household, and community safety"
                    ]
                }
            ]
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity",
                "Significant respiratory depression",
                "Severe bronchial asthma",
                "Paralytic ileus",
                "Management of acute pain or opioid analgesia required for short period of time",
                "Management of postoperative pain, including use after outpatient or day surgeries",
                "Management of mild pain",
                "Management of intermittent pain (not for PRN use)"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Respiratory depression is main hazard; may occur more frequently in elderly or debilitated patients, or in conditions associated with hypoxia or hypercapnia (even moderate therapeutic doses)",
                "Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia; opioid use increases risk of CSA in a dose-dependent fashion; in patients who present with CSA, consider decreasing opioid dosage using best practices for opioid taper",
                "CNS depression: May cause somnolence, dizziness, altered consciousness (including coma)",
                "Coadministration with alcohol, other CNS depressants, and illicit drugs may cause hypotension, profound sedation, and coma or respiratory depression",
                "QTc prolongation observed in healthy individuals at 40 mcg/hr; avoid in patients with history of Long QT Syndrome or coadministration with Class IA (eg, quinidine, procainamide, disopyramide) or Class III (eg, sotalol, amiodarone, dofetilide) antiarrhythmics",
                "Head injury: Respiratory depressant effects of opioids may include carbon dioxide retention and lead to elevated CSF pressure",
                "Hypotensive effects: Can cause severe hypotension; caution with depleted blood volume or coadministration of drugs that that affect vasomotor tone (eg, phenothiazines), vasodilators, or antihypertensives",
                "Misuse, abuse, diversion: Partial agonist at the mu opioid receptor and a Schedule III controlled opioids expose users to the risks of addiction, abuse, and misuse; there is a greater risk for overdose and death with extended-release opioids due to the larger amount of active opioid present (see Black Box Warnings)",
                "Serious, life-threatening, or fatal respiratory depression reported (see Black Box Warnings)",
                "Accidental exposure reported, including fatalities (see Black Box Warnings)",
                "Neonatal opioid withdrawal syndrome reported with long-term use during pregnancy (see Black Box Warnings)",
                "Do not abruptly discontinue buprenorphine in a patient physically dependent on opioids; when discontinuing therapy, in a physically dependent patient, gradually taper the dosage; rapid tapering in a patient physically dependent on opioids may lead to a withdrawal syndrome and return of pain",
                "Interactions with CNS depressants (eg, alcohol, sedatives, anxiolytics, hypnotics, neuroleptics, other opioids) can cause additive effects and increase risk for respiratory depression, profound sedation, and hypotension",
                "Hepatoxicity: Although not observed in buprenorphine transdermal chronic pain clinical trials, cases of cytolytic hepatitis and hepatitis with jaundice observed in individuals receiving buprenorphine SL for opioid dependence treatment",
                "Fever: If fever or increased core body temperature occurs following strenuous exertion, monitor for increased opioid adverse effects; adjust dose if necessary",
                "Similar to other opioids, may aggravate seizure disorders by lowering seizure threshold",
                "Special risk groups may experience increased adverse reactions; caution with alcoholism, delirium tremens, adrenocortical insufficiency, CNS depression, debilitation, kyphoscoliosis associated with respiratory compromise, myxedema or hypothyroidism, prostatic hypertrophy or urethral stricture, severe impairment of hepatic, pulmonary or renal function, and toxic psychosis",
                "May cause sphincter of Oddi spasm and aggravate abdominal conditions, including ileus",
                "Not recommended for use within 14 days of MAO inhibitors; severe and unpredictable potentiation by MAO inhibitors reported"
            ],
            "specific": [
                {
                    "type": "Opioid analgesic risk evaluation and mitigation strategy (REMS)",
                    "description": [
                        "To ensure that benefits of opioid analgesics outweigh risks of addiction, abuse, and misuse, the Food and Drug Administration (FDA) has required a Risk Evaluation and Mitigation Strategy (REMS) for these products",
                        "Discuss the safe use, serious risks, and proper storage and disposal of opioid analgesics with patients and/or their caregivers every time these medicines are prescribed; Use the following link to obtain the Patient Counseling Guide (PCG): www.fda.gov/OpioidAnalgesicREMSPCG",
                        "Emphasize to patients and their caregivers the importance of reading the Medication Guide that they will receive from their pharmacist every time an opioid analgesic is dispensed to them",
                        "Consider using other tools to improve patient, household, and community safety, such as patient-prescriber agreements that reinforce patient-prescriber responsibilities",
                        "To obtain further information on opioid analgesic REMS and for a list of accredited REMS CME/CE, call 1-800-503-0784, or log on to www.opioidanalgesicrems.com; the FDA Blueprint can be found at www.fda.gov/OpioidAnalgesicREMSBlueprint"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "23"
        },
        {
            "name": "Dizziness",
            "percent": "16"
        },
        {
            "name": "Headache",
            "percent": "16"
        },
        {
            "name": "Pruritus at application site",
            "percent": "15"
        },
        {
            "name": "Constipation",
            "percent": "14"
        },
        {
            "name": "Somnolence",
            "percent": "14"
        },
        {
            "name": "Vomiting",
            "percent": "11"
        },
        {
            "name": "Peripheral edema",
            "percent": "7"
        },
        {
            "name": "Xerostomia",
            "percent": "7"
        },
        {
            "name": "Erythema at application site",
            "percent": "7"
        },
        {
            "name": "Rash at application site",
            "percent": "6"
        },
        {
            "name": "Fatigue",
            "percent": "5"
        },
        {
            "name": "Hyperhidrosis",
            "percent": "4"
        },
        {
            "name": "Pruritus",
            "percent": "4"
        },
        {
            "name": "Falls",
            "percent": "4"
        },
        {
            "name": "Diarrhea",
            "percent": "3"
        },
        {
            "name": "Pain in extremity",
            "percent": "3"
        },
        {
            "name": "Insomnia",
            "percent": "3"
        },
        {
            "name": "Dyspnea",
            "percent": "3"
        },
        {
            "name": "Dyspepsia",
            "percent": "3"
        },
        {
            "name": "Urinary tract infection",
            "percent": "3"
        },
        {
            "name": "Back pain",
            "percent": "3"
        },
        {
            "name": "Joint swelling",
            "percent": "3"
        },
        {
            "name": "Hypoesthesia",
            "percent": "2"
        },
        {
            "name": "Arthralgia",
            "percent": "2"
        },
        {
            "name": "Stomach discomfort",
            "percent": "2"
        },
        {
            "name": "Rash",
            "percent": "2"
        },
        {
            "name": "Anorexia",
            "percent": "2"
        },
        {
            "name": "Paraesthesia",
            "percent": "2"
        },
        {
            "name": "Tremor",
            "percent": "2"
        },
        {
            "name": "Confusional state",
            "percent": "2"
        }
    ]
}